Product Recall: Peg-Intron® REDIPEN Injection

SOL Limited (Singapore Branch), a subsidiary of Merck& Co. Inc, is conducting a voluntary recall, to the pharmacy/retailer level, of all strengths of Peg-Intron® REDIPEN Injection as a precautionary measure due to a potential defect in the glass cartridge component of the product delivery system. As a result of this defect, a limited number of REDIPEN units may have a potential risk for contamination since the container seal may be compromised. With effect from 18 Sept 2010, all sales of Peg-Intron® REDIPEN Injections have been suspended and all existing stocks of all the affected batches will be recalled. Until unaffected units of Peg-Intron ® REDIPEN become available, healthcare professionals are advised NOT to initiate Peg-Intron ® treatment on NEW patients and to consider switching existing patients to alternative therapies. Published: 30 Sep 2010

Dear Healthcare Professional Letters